Trellus Health plc (TRLS.L)
GBp 0.58
(0.0%)
GBp 0.58
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 19 Thousand | 18 Thousand | 25 Thousand | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | 19 Thousand | 18 Thousand | 25 Thousand | - |
| Operating Expenses | 6.82 Million | 8.82 Million | 5.92 Million | 1.52 Million |
| Selling, General and Administrative Expenses | 1.96 Million | 8.82 Million | 5.92 Million | 1.52 Million |
| Research and Development Expenses | - | 593 Thousand | 22 Thousand | - |
| Other Expenses | 4.85 Million | - | - | - |
| Cost and Expenses | 6.82 Million | 8.82 Million | 5.92 Million | 1.52 Million |
| Operating Income | -6.8 Million | -8.81 Million | -5.9 Million | -1.52 Million |
| Interest Expense | - | - | - | - |
| Income Tax Expense | - | -123 Thousand | -204.55 Thousand | - |
| Earnings before Tax | -6.33 Million | -8.81 Million | -5.9 Million | -1.52 Million |
| Net Income | -6.33 Million | -8.81 Million | -5.9 Million | -1.52 Million |
| Earnings Per Share Basic | -0.04 | -0.05 | -0.04 | -0.02 |
| Earnings Per Share Diluted | -0.04 | -0.05 | -0.04 | -0.02 |
| Weighted Average Shares Outstanding | 161.5 Million | 161.5 Million | 131.73 Million | 84.03 Million |
| Weighted Average Shares Outstanding (Diluted) | 161.5 Million | 161.5 Million | 131.73 Million | 84.03 Million |
| Gross Margin | 1.00 | 1.00 | 1.00 | - |
| EBIT Margin | -307.68 | -459.67 | -234.80 | - |
| Profit Margin | -333.63 | -489.44 | -236.08 | - |
| EBITDA | -5.84 Million | -8.27 Million | -5.87 Million | -1.52 Million |
| Earnings Before Tax Margin | -358.05 | -489.44 | -236.08 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 25 Thousand | 25 Thousand | 19 Thousand | 2500.00 | 2500.00 | 7000.00 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | 25 Thousand | 25 Thousand | 19 Thousand | 2500.00 | 2500.00 | 7000.00 |
| Operating Expenses | 2.05 Million | 2.05 Million | 6.82 Million | 1.52 Million | 1.52 Million | 1.88 Million |
| Selling, General and Administrative Expenses | 2.05 Million | 2.05 Million | - | 1.05 Million | 1.05 Million | 1.88 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | 478.5 Thousand | - | - |
| Cost and Expenses | 2.05 Million | 2.05 Million | 6.82 Million | 1.52 Million | 1.52 Million | 1.88 Million |
| Operating Income | -2.02 Million | -2.02 Million | -6.8 Million | -1.52 Million | -1.52 Million | -1.87 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | 241 Thousand | - | - | - |
| Earnings before Tax | -1.94 Million | -1.94 Million | -6.33 Million | -1.38 Million | -1.38 Million | -1.78 Million |
| Net Income | -1.94 Million | -1.94 Million | -6.33 Million | -1.38 Million | -1.38 Million | -1.78 Million |
| Earnings Per Share Basic | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 |
| Earnings Per Share Diluted | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 |
| Weighted Average Shares Outstanding | 161.51 Million | 161.51 Million | 161.5 Million | 161.51 Million | 161.51 Million | 161.51 Million |
| Weighted Average Shares Outstanding (Diluted) | 161.5 Million | 161.5 Million | 161.5 Million | 161.5 Million | 161.5 Million | 161.5 Million |
| Gross Margin | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| EBIT Margin | -80.42 | -80.42 | - | -604.40 | -604.40 | -265.43 |
| Profit Margin | -77.82 | -77.82 | -333.63 | -554.40 | -554.40 | -254.79 |
| EBITDA | -2.01 Million | -2.01 Million | - | -1.51 Million | -1.51 Million | -1.85 Million |
| Earnings Before Tax Margin | -81.08 | -81.08 | -358.05 | -610.80 | -610.80 | -267.79 |
GADS
SCKT
2121
TMIS
GWSN
FKWL